Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem

卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测

• 批准号: 10621734
• 负责人: ANDREW K. GODWIN
• 金额: $ 59.3万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10621734
• 关键词: 3-Dimensional; Advanced Malignant Neoplasm; Advisory Committees; Area; BRCA mutations; Benign; Biological Assay; Biological Markers; Biology; Biopsy; Blood; Blood capillaries; Blood specimen; Body Fluids; CA-125 Antigen; Cancer Control; Cancer Detection; Cancer Diagnostics; Cancer Patient; Cancer cell line; Carcinoma in Situ; Cell Line; Circulation; Clinical; Clinical Sensitivity; Colon Carcinoma; Communication; Companions; Detection; Development; Diagnosis; Diagnostic Sensitivity; Disease; Drops; Early Diagnosis; Engineering; Epithelial ovarian cancer; Excision; Fingerprint; General Population; Generations; Goals; Human; Immune response; Immunoassay; Immunoprecipitation; Intervention; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of ovary; Mammalian Oviducts; Mass Spectrum Analysis; Messenger RNA; Methods; MicroRNAs; Microfluidics; Nanochip Analytical Device; Neoplasm Circulating Cells; Operative Surgical Procedures; Outcome; Ovarian; Ovary; Pathway interactions; Patients; Pattern; Plasma; Play; Population Control; Printing; Proteins; Proteomics; Public Health; Reporting; Reproducibility; Risk; Role; Sampling; Screening for Ovarian Cancer; Screening for cancer; Sensitivity and Specificity; Serous; Serum Markers; Signaling Protein; Solid Neoplasm; Source; Specificity; Specimen; Symptoms; Technology; Testing; Time; Tissues; Training; Tumor Antigens; Tumor Markers; Tumor stage; Tumor-Derived; Ultrasonography; Untranslated RNA; Vagina; Validation; Vesicle; Woman; biomarker panel; cancer diagnosis; candidate marker; candidate validation; clinical diagnosis; clinical translation; cost; curative treatments; detection assay; diagnostic platform; disorder risk; early detection biomarkers; effusion; exosome; extracellular vesicles; high risk population; imaging modality; innovation; liquid biopsy; malignant breast neoplasm; microchip; microfluidic technology; microsystems; mortality; mutation carrier; nano; nanoengineering; nanomaterials; nanopattern; neoplastic cell; novel; novel marker; patient prognosis; pre-clinical; presymptomatic testing; prevention service; protein biomarkers; protein profiling; routine screening; screening; self assembly; tool; treatment response; tumor; tumor progression

PROJECT SUMMARY Ovarian cancer is a silent killer that strikes with few, if any, symptoms. By the time a woman knows she has it, the cancer is often advanced and the outlook grim. However, if epithelial ovarian cancer is caught early the prognosis for the patient is excellent. Developing non-invasive and highly specific blood-based tests for pre- symptomatic screening and early detection of ovarian cancer is therefore crucial. This is especially essential since obtaining a biopsy is difficult, costly, and sometimes not even an option. In addition, most blood biomarkers to date lack the necessary sensitivity and specificity for early detection of this silent killer. A fundamental challenge is the extremely low concentrations of circulating biomolecules released from the developing tumors at pre-clinical stages which can be 10,000-fold lower than their clinically detectable levels. Therefore, there is a pressing need to uncover novel biomarkers, apply new strategies, and develop robust technologies to propel the advancement of cancer diagnostics, especially in a disease such as ovarian cancer. We have focused our efforts on small extracellular vesicles (sEVs), primarily small and large exosomes derived from the endolysosomal pathway, which play important roles in cellular communication, immune response, and cancer progression via transfer of a selective repertoire of biomolecules. sEVs/exosome release is significantly increased in most neoplastic cells, including ovarian cancer and occurs continuously at all stages of tumor development. Tumor- derived sEVs accumulate in human blood and malignant effusions. These vesicles carry enriched subsets of biomolecules mirroring the tumor cells of origin, such as signaling proteins, tumor antigens, and functional RNAs (mRNA and miRNAs), which offer a new strategy to surmount the challenge in reliable detection of intrinsically low-level serum markers during early malignant transformation. Thus, the constitutive release and enrichment of certain tumor markers within sEVs present distinctive opportunities for early cancer diagnosis. We hypothesize that circulating sEVs, much akin to circulating tumor cells but more robust due to their active release and incredible stability in bodily fluids, represent a greater source for the discovery of exo-biomarkers for early detection, potentially while still confined to the fallopian tube. In addition, sEVs can serve as a 'liquid biopsy’ to assess benefits and treatment responses in real time in cancer patients. Our innovative application merges EV biology with nano-material/microfluidic technology to develop an advanced microfluidic platform to capture and detect ovarian cancer-derived sEVs with high specificity and sensitivity from the circulation. This approach will integrate validated fallopian tube and ovarian cancer associated exo-protein biomarkers (SA1), which will be applied to a second-generation nano-engineered EV analysis chip (SA2). These studies will be followed by clinical validation using longitudinal samples collected from asymptomatic women who later develop epithelial ovarian cancer (SA3). Our ultimate goal is to develop a reliable blood-based assay that, when used in conjunction with current screening approaches will decrease the mortality from ovarian cancer.

项目总结 卵巢癌是一种沉默的杀手，几乎没有任何症状。当一个女人知道她有这种病的时候， 癌症通常是晚期的，前景黯淡。然而，如果卵巢上皮癌被及早发现， 病人的预后很好。开发非侵入性和高度特异的基于血液的检测方法 因此，对卵巢癌进行有症状的筛查和早期发现至关重要。这一点尤其重要。 因为获得活组织检查是困难的、昂贵的，有时甚至不是一个选择。此外，大多数血液生物标志物 迄今为止，缺乏必要的敏感性和特异性，无法及早发现这个沉默的杀手。一项基本原则 挑战是正在发展的肿瘤释放的极低浓度的循环生物分子 在临床前阶段，可能比临床可检测到的水平低10,000倍。因此，有一个 迫切需要发现新的生物标记物，应用新的战略，并开发强有力的技术来推动 癌症诊断学的进展，尤其是在卵巢癌等疾病中。我们已经集中力量 在小细胞外小泡(SEV)上，主要是来自内溶酶体的小的和大的外体 途径，在细胞通讯、免疫反应和癌症进展中发挥重要作用 一种生物分子选择性保存库的转移。SEV/Exosome的释放显著增加 肿瘤细胞，包括卵巢癌，在肿瘤发展的所有阶段持续发生。肿瘤- 衍生的SEV积聚在人的血液和恶性积液中。这些囊泡携带丰富的亚群 反映起源的肿瘤细胞的生物分子，如信号蛋白、肿瘤抗原和功能RNA (mRNA和miRNAs)，它们提供了一种新的策略，以克服在可靠地检测固有的 早期恶变过程中的低水平血清标志物。因此，结构性释放和浓缩 SEV中某些肿瘤标志物的存在为早期癌症诊断提供了独特的机会。我们 假设循环中的SEV，非常类似于循环中的肿瘤细胞，但由于它们的主动释放而更加健壮 体液中令人难以置信的稳定性，为早期发现外生物标志物提供了更大的来源 检测，可能仍局限于输卵管。此外，SEV还可以作为“液体活组织检查” 实时评估癌症患者的益处和治疗反应。我们的创新应用融合了电动汽车 利用纳米材料/微流控技术开发先进的微流控平台，以捕获和 从循环中检测卵巢癌来源的SEV具有高特异性和敏感性。这一方法将 整合有效的输卵管和卵巢癌相关外源蛋白生物标记物(SA1)，这将是 应用于第二代纳米工程电动汽车分析芯片(SA2)。在这些研究之后，将 从后来发展为上皮样病变的无症状妇女收集纵向样本的临床验证 卵巢癌(SA3)。我们的最终目标是开发一种可靠的基于血液的分析方法，当用于 与目前的筛查方法相结合，将降低卵巢癌的死亡率。